Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Fluvoxamine
Drug ID BADD_D00950
Description Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine.
Indications and Usage Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) [FDA Label]. Has also been used in the management of bulimia nervosa [A250].
Marketing Status Prescription; Discontinued
ATC Code N06AB08
DrugBank ID DB00176
KEGG ID D07984
MeSH ID D016666
PubChem ID 5324346
TTD Drug ID D03HFG
NDC Product Code Not Available
Synonyms Fluvoxamine | Fluvoxadura | Fluvoxamin AL | Fluvoxamin beta | Fluvoxamin Stada | Fluvoxamin-neuraxpharm | Fluvoxamin neuraxpharm | Fluvoxamin-ratiopharm | Fluvoxamin ratiopharm | ratio-Fluvoxamine | ratio Fluvoxamine | Fluvoxamina Geminis | Geminis, Fluvoxamina | Fluvoxamine Maleate | Fluvoxamine Maleate, (E)-Isomer | Fluvoxamine, (Z)-Isomer | Luvox | Floxyfral | Fevarin | Dumirox | Faverin | Novo-Fluvoxamine | Novo Fluvoxamine | Nu-Fluvoxamine | Nu Fluvoxamine | PMS-Fluvoxamine | PMS Fluvoxamine | Desiflu | DU-23000 | DU 23000 | DU23000
Chemical Information
Molecular Formula C15H21F3N2O2
CAS Registry Number 54739-18-3
SMILES COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Poisoning and toxicityCytochrome P450 2D6P10635T57392Not Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neck pain15.03.04.009--
Neoplasm16.16.02.001--Not Available
Nephrolithiasis20.04.01.002--
Nervous system disorder17.02.10.001--Not Available
Nervousness19.06.02.003--Not Available
Neuralgia17.02.07.005--
Neuroleptic malignant syndrome15.05.04.015; 12.03.01.003; 08.05.01.005; 17.05.02.003--Not Available
Neuropathy peripheral17.09.03.003--Not Available
Neurosis19.06.01.001--Not Available
Nocturia20.02.03.001--Not Available
Obesity14.03.02.009--
Obsessive thoughts19.06.05.001--Not Available
Obsessive-compulsive personality disorder19.05.04.001--Not Available
Oedema14.05.06.010; 08.01.07.006--Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.007--
Oesophagitis07.08.05.001--
Oliguria20.01.03.004--Not Available
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Osteoarthritis15.01.04.001--Not Available
Otitis media11.01.05.004; 04.05.01.001--
Pain08.01.08.004--
Pallor24.03.04.001; 23.03.03.031; 08.01.03.032--Not Available
Palpitations02.01.02.003--
Pancreatitis07.18.01.001--
Paraesthesia17.02.06.005--
Paralysis17.01.04.004--Not Available
Paranoia19.05.01.005--Not Available
Parkinsonism17.01.05.003--Not Available
Parosmia22.04.03.007; 17.04.04.002--Not Available
Pelvic pain20.02.03.007; 07.01.06.012; 21.10.01.001--
The 9th Page    First    Pre   9 10 11 12 13    Next   Last    Total 14 Pages